G
Gisela Schwab
Researcher at Exelixis
Publications - 22
Citations - 4675
Gisela Schwab is an academic researcher from Exelixis. The author has contributed to research in topics: Cabozantinib & Everolimus. The author has an hindex of 12, co-authored 22 publications receiving 3005 citations. Previous affiliations of Gisela Schwab include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou-Alfa,Tim Meyer,Ann-Lii Cheng,Anthony B. El-Khoueiry,Lorenza Rimassa,Baek Yeol Ryoo,Irfan Cicin,Philippe Merle,Yen-Hsun Chen,Joong-Won Park,Jean-Frédéric Blanc,Luigi Bolondi,Heinz Josef Klümpen,Heinz Josef Klümpen,Stephen L. Chan,Vittorina Zagonel,Tiziana Pressiani,Min Hee Ryu,Alan P. Venook,Alan P. Venook,Colin Hessel,Anne E. Borgman-Hagey,Gisela Schwab,Robin Kate Kelley +23 more
TL;DR: Treatment with cabozantinib resulted in longer overall survival and progression‐free survival than placebo among patients with previously treated advanced hepatocellular carcinoma, and the rate of high‐grade adverse events in the cabozaninib group was approximately twice that observed in the placebo group.
Journal ArticleDOI
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Toni K. Choueiri,Bernard Escudier,Thomas Powles,Paul N. Mainwaring,Brian I. Rini,Frede Donskov,Hans J. Hammers,Thomas E. Hutson,Jae-Lyun Lee,Katriina Peltola,Bruce J. Roth,Georg A. Bjarnason,Lajos Géczi,Bhumsuk Keam,Pablo Maroto,Daniel Y.C. Heng,Manuela Schmidinger,Philip W. Kantoff,Anne E. Borgman-Hagey,Colin Hessel,Christian Scheffold,Gisela Schwab,Nizar M. Tannir,Robert J. Motzer +23 more
TL;DR: Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.
Journal ArticleDOI
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Toni K. Choueiri,Thomas Powles,Mauricio Burotto,Bernard Escudier,Maria T Bourlon,B. Zurawski,Victor M. Oyervides Juárez,James J. Hsieh,Umberto Basso,Amishi Yogesh Shah,Cristina Suárez,Alketa Hamzaj,Jeffrey C. Goh,Carlos Barrios,Martin Eduardo Richardet,C. Porta,Ruben Dario Kowalyszyn,Juan P. Feregrino,Jakub Żołnierek,David Pook,Elizabeth R. Kessler,Yoshihiko Tomita,Ryuichi Mizuno,Jens Bedke,Joshua Zhang,Matthew Maurer,Burcin Simsek,Flavia Ejzykowicz,Gisela Schwab,Andrea B. Apolo,Robert J. Motzer +30 more
TL;DR: Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with previously untreated advanced renal-cell carcinoma.
Journal ArticleDOI
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri,Bernard Escudier,Thomas Powles,Nizar M. Tannir,Paul N. Mainwaring,Brian I. Rini,Hans J. Hammers,Frede Donskov,Bruce J. Roth,K. Peltola,Jae-Lyun Lee,Daniel Y.C. Heng,Manuela Schmidinger,Neeraj Agarwal,Cora N. Sternberg,David F. McDermott,Dana T. Aftab,Colin Hessel,Christian Scheffold,Gisela Schwab,Thomas E. Hutson,Sumanta K. Pal,Robert J. Motzer +22 more
TL;DR: The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment.
Journal ArticleDOI
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
TL;DR: The successful development of panitumumab represents a milestone for mice engineered with a human humoral immune system and their future applications as treatment for people with advanced colorectal cancer.